Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.57 |
| ▸ | NOS2 | P35228 | 5/20 | 0.55 |
| ▸ | NOS1 | P29475 | 3/20 | 0.55 |
| ▸ | NOS3 | P29474 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378689 | 0.86 | NOS2 (0.59) | ADORA1NOS2NOS1NOS3AURKA | |
| SCHEMBL31569166 | 0.84 | NOS2 (0.53) | ADORA1NOS2NOS1NOS3AURKA | |
| SCHEMBL9041424 | 0.83 | NOS1 (0.56) | ADORA1NOS2NOS1NOS3AURKA | |
| SCHEMBL9648738 | 0.82 | PI4KA (0.57) | ADORA1NOS2NOS1NOS3AURKA | |
| SCHEMBL9406654 | 0.81 | NOS2 (0.58) | ADORA1NOS2NOS1NOS3AURKA | |
| SCHEMBL9406720 | 0.81 | PI4KA (0.56) | NOS2NOS1NOS3AURKAPRMT5 | |
| SCHEMBL6305824 | 0.79 | AURKA (0.58) | ADORA1NOS2NOS1NOS3AURKA | |
| SCHEMBL8561715 | 0.78 | ADORA1 (0.41) | ADORA1NOS2NOS1NOS3PRMT5 | |
| SCHEMBL1667426 | 0.76 | KDM5A (0.48) | ADORA1ADORA3ADORA2A | |
| SCHEMBL9201844 | 0.75 | ADORA1 (0.53) | ADORA1NOS2NOS1NOS3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2125806-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | Pfizer Products Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008084303-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-0520423-B1 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6100252-A | SPECIFIED COMPOUNDS INCLUDING METHYL 2-BUTYL-1-((2'-(2-OXO-3H-1,2,3,5-OXATHIADIAZOL-4-YL)BIPHENYL) METHYL)-BENZIMIDAZOLE-7-CARBOXYLATE; USE TO TREAT CIRCULATORY DISEASES SUCH AS HYPERTENSIVE DISEASES AND HEART DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-5883111-A | STRONG AND LONG-LASTING ACTION BY ORAL ADMINISTRATION; HYPOTENSIVE AGENTS; CARDIOTONIC AGENTS; ALZHEIMER'S DISEASE; | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-16 | — | — | US | disclosed |
| US-5736555-A | HYPOTENSIVE AGENTS; FDA ORANGE BOOK LISTED PATENT FOR AZILSARTAN MEDOXOMIL | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-07 | — | — | US | disclosed |
| US-5583141-A | ADMINISTERING AS THERAPEUTIC AGENTS OF CIRCULATORY DISEASES; AZILSARTAN; ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| EP-0517812-A4 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO INC (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5449682-A | Angiotensin II antagonists incorporating a substituted benzyl element | MERCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0513979-A1 | Angiotensin II antagonists incorporating a substituted thiophene or furan | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0510813-A1 | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle | MERCK & CO. INC. (US) | 1992-10-28 | — | — | EP | disclosed |
| US-5157026-A | Oxo-purines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0508723-A1 | Angiotensin II antagonists incorporating an indole or dihydroindole | MERCK & CO. INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5151435-A | Hypotensive agents, glaucoma and cognition activators | MERCK & CO., INC. (US) | 1992-09-29 | — | — | US | disclosed |
| EP-0503838-A2 | Heterocyclic compounds bearing acidic functional groups as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-09-16 | — | — | EP | disclosed |
| US-5128327-A | Hypotensive agents; congestive heart failure; antidepressants; anxiolytic agents; cognition activators | MERCK & CO., INC. (US) | 1992-07-07 | — | — | US | disclosed |
| US-5102880-A | Biphenyl imidazotriazine derivatives; Hypotensive and cardiotonic agents | MERCK & CO., INC. (US) | 1992-04-07 | — | — | US | disclosed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | AGTR2, AGTR1, AGT | ADORA1 1622/4885NOS2 1246/4885NOS1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.